Home | Publications | Therapeutic place holder
place holder place holder

Therapeutic

Anti Addiction Therapies, 2006-2011- The Pharmaceutical Industry's Next Viagra?


Publication Date   October 2006
Publisher   Visiongain
Product Type   Report
Pages   126
ISBN Number   not applicable
Product Code   VIS042
Ask a question about this product?

Price £1,499.00

approximately: $2,647 | €1,901

Summary


Please Note: Reports are sold based on the user licenses indicated. The reports will be accessible in Flash format via an online reading room on the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order, the client will receive an email with information on accessing their purchase.

Doctors and concerned specialists have long maintained a behavioural-based approach to treating addiction is the most effective treatment programme. Suggested pharmaceutical solutions simply did not work. That is it seems...until now. Two leading pharmaceutical companies have developed novel drugs that could revolutionise the treatment of obesity and nicotine addiction. And what is more, those drugs could save health authorities millions of dollars. With the pharmaceutical industry anxiously seeking the next blockbuster product, it is hardly surprising that Chantix and Acomplia are generating so much interest. Are these drugs set to shift the focus of the pharmaceutical industry? Find out today.

Will these drugs really make much of a difference for such complex disorders? Is this not just the industry wary of decline seizing an opportunity to make money? This report assesses the currently available drugs, analysing which pipeline drugs appear to fit unmet needs best. This report also examines which pharmaceutical companies are likely to be market leaders by 2011.

Pfizer's Chantix, for the treatment of nicotine addiction, and Sanofi-Aventis' Acomplia might provide not only much needed effective relief to thousands of addicts, but could also help develop and drive a market as Viagra did for erectile dysfunction. Markets that are currently worth $1 billion could multiply several-fold within the foreseeable future.

Treatment can be tailored to the individual and typically involve a combination of drug and behavioural therapy. Treatment of drug addiction is usually a long, multi-stage process. Encouragingly, modern drug-dependency treatment regimes are generally believed to be effective, with 40-70% of patients successfully recovering from their addiction. Can that same success be repeated in other addictions?

What is in the report?

  • Statistics of addiction, including potential patient populations and the economic burden of addiction.
  • Drug addiction - Heroin and cocaine addiction treatments, including the development of vaccinations for cocaine addiction.
  • Alcohol addiction - A review of the new products for the treatment of alcohol addiction, largely those that have been indicated for the treatment of depression or opioid addiction.
  • Smoking addiction - Potentially a huge market. Many health authorities have placed smoking as a priority. Pfizer have recently launched Chantix, which is likely to be the first specific treatment for smoking that is an alternative to the nicotine replacement.
  • Gambling addiction - A market that is more potential than current reality. It faces difficulties in both developing effective treatments and overcoming cultural perception that gambling is not something that should necessarily be treated by a pharmaceutical.
  • Obesity treatment - Potentially the largest market. The prevalence of obesity is increasing, with Sanofi-Aventis having recently launched Acomplia.
  • Pipeline products - The interest in the addiction markets stems from the potentially large patient populations and also the large number of products in the pipeline.
  • World market by country region for the specific treatment markets. Specific drivers and restraints for the addiction treatment markets are considered.
  • Unique research and primary information unavailable elsewhere

Companies mentioned in the report:

  • Abbott Laboratories
  • Aktiv-Dry
  • Alizyme
  • Alkermes
  • Alpharma
  • Amgen
  • Amylin
  • Arena
  • Britannia Pharmaceuticals
  • BioTie Therapies
  • British American Tobacco
  • Celtic Pharma
  • Cephalon
  • Cetilistat
  • Cytos Biotech
  • DrugAbuse Sciences
  • Eisai
  • Forest
  • Fujisawa
  • Fulcrum Pharma
  • GSK
  • Hokuriku Seiyaku
  • Hythiam
  • INSERM
  • Johnson & Johnson
  • Lipha Pharmaceuticals
  • Merck
  • Merck KGaA
  • Metabolic
  • Nabi Pharmaceuticals
  • Nastech
  • New River Pharmaceuticals
  • Nippon Shinyaku
  • Novartis
  • Peptimmune genzyme
  • Pfizer
  • Philip Morris
  • Phytopharm
  • Pliva
  • Reckitt Benckiser
  • Roche
  • Sanofi-Aventis
  • Schering-Plough
  • Shionogi
  • Shire
  • Somaxon
  • Titan Pharmaceuticals
  • Unilever
  • Valera
  • Vernalis
  • Xenova
  • 7TM Pharma

Content


  • 1. Executive Summary
  • 2. Introduction
    • 2.1 Drug Addiction/Abuse/Dependency Definitions
    • 2.2 The Development of Drugs Specifically for Treating Addiction
    • 2.3 Maintenance Treatment is Controversial
    • 2.4 Objectives, Methodology and Scope
  • 3. The Physiology and Psychology of Addiction
    • 3.1. Addiction Affects Many Areas of the Brain
    • 3.2. Dopamine is Key
    • 3.3. GABA Imbalance Incites Craving
    • 3.4. The Psychology of Addiction
  • 4. Regional Prevalence of Addiction
    • 4.1 The Economic Cost of Addiction
    • 4.2 Drug Dependency Low, But Severe Hazard
    • 4.3 Alcohol Dependency Increasing Despite Health Consequences
    • 4.4 Smoking Prevalence Causes Highest Fatality Rates From Dependency
    • 4.5 Associated Problems Increase With Gambling Increase
  • 5. Drug Addiction
    • 5.1 Heroin - The Most Serious of all Addictions?
    • 5.2 What Happens When Heroin is Taken?
      • 5.2.1 Withdrawal Symptoms
    • 5.3 Drug Addiction Treatments
      • 5.3.1 Opioid Addiction Has Well Tried Treatments
    • 5.4 Opioid Dependence Treatment Regimes
    • 5.5 Naltrexone Implants Remain Expensive
    • 5.6 Cocaine Addiction Looks To Future Success
    • 5.7 Cocaine Treatment - A Vaccine Available Soon?
      • 5.7.1 Drugs to reduce symptoms of cocaine abstinence or craving
    • 5.8 Market Outlook For Drug Addiction Treatments
      • 5.8.1 Cocaine Addiction Treatments Hold Greatest Promise
    • 6. Alcohol Addiction
      • 6.1 The Effects and Problems Associated With Alcohol
      • 6.2 Alcohol dependency tests
      • 6.3 Alcohol Addiction Treatments
        • 6.3.1 Antabuse - Available Since 1948
        • 6.3.2 Naltrexone Now Available in Injectable Form
      • 6.4 Campral Offers Another Mode of Action for Alcohol Dependency Treatment
      • 6.5 Most Recent Alcohol Dependency Drug From J&J
      • 6.6 Serotonergic Agents Show Limited Usefulness
      • 6.7 Drug treatment for related disorders
      • 6.8 Market Outlook For Alcohol Dependency Treatments
    • 7. Smoking Addiction
      • 7.1 How to assess the level of nicotine addiction?
      • 7.2 Smoking Addiction Treatments
        • 7.2.1 Chantix is the Latest Anti-smoking Treatment
        • 7.2.2 NRT Dominates Smoking Treatment Therapies
        • 7.2.3 Zyban Provides Effective Treatment
      • 7.3 Beneficial Effects Are Quickly Noticeable
      • 7.4 Withdrawal Effects Are Also Quickly Noticeable
      • 7.5 Market Outlook for Nicotine Dependency Treatments
    • 8. Gambling Addiction
      • 8.1 Gambling Addiction Treatments
        • 8.1.1 Opioid Antagonists (OA)
        • 8.1.2 Selective Serotonin Reuptake Inhibitors (SSRIs)
        • 8.1.3 Mood Stabilisers
        • 8.1.4 Other Pharmaceutical Treatment Options for Gambling Treatment
      • 8.2 Market Outlook for Gambling Addiction Treatments
    • 9. Obesity and Food Addiction
      • 9.1 Obesity and Food Addiction Treatments
      • 9.2 Will Acomplia Accomplish More?
      • 9.3 Other Opportunities For Obesity Treatment
        • 9.3.1 Hormone Treatment Greeted With Optimism
      • 9.4 Market Outlook for Obesity Treatments
    • 10. World Market by Region
      • 10.1 Drivers and Restraints
      • 10.2 The US Market Presents Considerable Opportunities
      • 10.3 The Japanese Market May Accept Treatments on a Limited Scale
      • 10.4 US Market Is Surprisingly Undeveloped For Addiction Treatments
    • 11. Unmet Needs in Addiction Treatments
      • 11.1 Pipeline Products for the Treatment of Drug Addiction
      • 11.2 Fulcrum's Link With Celtic Could Produce Novel Addiction Therapies
      • 11.3 Genetic Link Between Disorders Inspires Further Research
      • 11.4 Drug addiction
        • 11.4.1 Opioid Addiction
        • 11.4.2 Cocaine Addiction
      • 11.5 Alcohol Addiction
      • 11.6 Smoking Addiction
      • 11.7 Grants From the US NIDA Used to Develop Nicotine Vaccination
      • 11.8 Gambling Addiction
      • 11.9 Obesity Food Addiction - Huge Interest in Potentially Lucrative Market
    • 12. Sanofi-Aventis: A Review
      • 12.1 The Takeover of Aventis By Sanofi was Aggressive
      • 12.2 Sanofi-Aventis Continues to Expand
    • 13. Conclusion
    • Tables and Figures
      • Table 5.1 A Comparison of the Heroin Dependency Treatment Options
      • Table 7.1 Leading Available NRT Products
      • Table 7.2 Beneficial Effects of Smoking Cessation
      • Table 7.3 The Duration of Smoking Withdrawal Effects
      • Table 7.4 World Revenue ($m) for Chantix, 2005-2011
      • Table 9.1 World Revenue ($m) for Acomplia, 2005-2011
      • Table 10.1 Leading Drugs For The Addiction Treatment Markets
      • Table 10.2 World Revenue ($m) and Growth Rate (%) of the Obesity Treatment Market, by Region, 2005
      • Table 10.3 World Revenue ($m) and Growth Rate (%) of the Nicotine Addiction Treatment Market, by Region, 2005
      • Table 10.4 World Revenue ($m) and Growth Rate (%) of the Alcohol Dependency Treatment Market, by Region, 2005
      • Table 11.1 Pipeline Products For Anti-Drug Addiction Treatments
      • Table 11.2 Pipeline Products for Cocaine Addiction Treatment
      • Table 11.3 Pipeline Products for Alcohol Dependency Treatment
      • Table 11.4 Pipeline Products for Obesity Treatment
      • Table 11.5 Pipeline Products for Gambling Addiction
      • Table 11.6 Selected Key Pipeline Products For Obesity Treatment
      • Figure 1.1 World Revenue ($m) for Acomplia, 2005-2011
      • Figure 6.1 Alcohol Consumption in Young Adults (18-29 years)
      • Figure 6.2 Percentage of Children Aged 15-16 Drunk Over 20 Times in Lifetime
      • Figure 7.1 World Revenue ($m) for Chantix, 2005-2011
      • Figure 9.1 World Revenue ($m) for Acomplia, 2005-2011
      • Figure 10.1 Market Share (%) for Obesity Treatments by Region, 2005
      • Figure 10.2 Market Share (%) for Nicotine Addiction Treatments by Region, 2005
      • Figure 10.3 Market Share (%) for Nicotine Addiction Treatments by Region, 2005